Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

986 ARTÍCULOS , VIENDO DEL 931 AL 945

Efficacy and safety of N-acetyl-L-leucine in patients with ataxia telangiectasia: A randomized, double-blind, placebo-controlled, crossover clinical trial

Beyraghi-Tousi M, Sahebkar A, Houra M, Sarvghadi P, Jamialahmadi T, Bagheri R, Tavallaie S, Gumpricht E, Saberi-Karimian M.

Eur J Paediatr Neurol. 2024 May;50:57-63. doi: 10.1016/j.ejpn.2024.04.009. Epub 2024 Apr 22.

Gait ataxia in alcohol use disorder: A systematic review

Mistarz N, Canfield L, Nielsen DG, Skøt L, Mellentin AI.

Psychol Addict Behav. 2024 Jun;38(4):507-517. doi: 10.1037/adb0000958. Epub 2023 Sep 28.

Pioglitazone as a Possible Treatment for Ataxia-Telangiectasia

Shackelford R.

Biomolecules. 2024 Oct 8;14(10):1264. doi: 10.3390/biom14101264.

Clinical characteristics of BRAT1-related disease: a systematic literature review

Kong W, Cao X, Lu C.

Acta Neurol Belg. 2024 Aug;124(4):1281-1288. doi: 10.1007/s13760-024-02507-y. Epub 2024 Apr 12.

Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Zielen S, Crawford T, Benatti L, Magnani M, Kieslich M, Ryan M, Meyts I, Gulati S, Borgohain R, Yadav R, Pal P, Hegde A, Kumar S, Venkateswar A, Udani V, Vinayan KP, Nissenkorn A, Fazzi E, Leuzzi V, Stray-Pedersen A, Pietrucha B, Pascual SI, Gouider R, Koenig MK, Wu S, Perlman S, Thye D, Janhofer G, Horn B, Whitehouse W, Lederman H.

Lancet Neurol. 2024 Sep;23(9):871-882. doi: 10.1016/S1474-4422(24)00220-5.

Evaluating mFARS in pediatric Friedreich's ataxia: Insights from the FACHILD study

Rummey C, Perlman S, Subramony SH, Farmer J, Lynch DR.

Ann Clin Transl Neurol. 2024 May;11(5):1290-1300. doi: 10.1002/acn3.52057. Epub 2024 Mar 31.

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, Grombacher T, Locatelli G, Szucs Z, Gounaris I, de Bono JS.

Clin Cancer Res. 2024 May 15;30(10):2057-2067. doi: 10.1158/1078-0432.CCR-23-2409.

Spinocerebellar ataxia type 11 (SCA11): TTBK2 variants, functions and associated disease mechanisms

Felício D, Santos M.

Cerebellum. 2024 Apr;23(2):678-687. doi: 10.1007/s12311-023-01540-6. Epub 2023 Mar 9.

Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?

Pilotto F, Del Bondio A, Puccio H.

Cells. 2024 Feb 9;13(4):319. doi: 10.3390/cells13040319.

Ataxic hemiparesis: a narrative review for clinical practice in rehabilitation

Sung MF, Lim JH.

Top Stroke Rehabil. 2024 Jul;31(5):537-545. doi: 10.1080/10749357.2023.2281722. Epub 2023 Nov 15.

I(123)-FP-CIT (DaTSCAN) SPECT beyond the Most Common Causes of Parkinsonism: A Systematic Review

Quintas S, Sanles-Falagan R, Berbís MÁ.

Mov Disord Clin Pract. 2024 Jun;11(6):613-625. doi: 10.1002/mdc3.14055. Epub 2024 May 1.

Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia

Pilotto F, Chellapandi DM, Puccio H.

Trends Mol Med. 2024 Feb;30(2):117-125. doi: 10.1016/j.molmed.2023.12.002. Epub 2024 Jan 24.

Effects of Non-Invasive Brain Stimulation for Degenerative Cerebellar Ataxia: A Systematic Review and Meta-Analysis

Matsugi A, Ohtsuka H, Bando K, Kondo Y, Kikuchi Y.

Mov Disord Clin Pract. 2024 Nov;11(11):1323-1334. doi: 10.1002/mdc3.14205. Epub 2024 Sep 2.

Autoimmune Neurobeachin Cerebellar Ataxia

Basal E, Gilligan M, Lesnick C, McKeon A.

Mov Disord. 2024 Dec;39(12):2271-2275. doi: 10.1002/mds.29991. Epub 2024 Aug 20.

Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia

Dentoni M, Florean I, Farina A, Joubert B, Do LD, Honnorat J, Damato V, Fabris M, Gigli GL, Valente M, Vogrig A.

Cerebellum. 2024 Dec;23(6):2308-2323. doi: 10.1007/s12311-024-01727-5. Epub 2024 Aug 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias